LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal…
Author: Business Wire
ZEISS Vision Care and Medical Eyeglass Center Form Strategic Partnership, Combining Optical Excellence with Patient-Centric Operational Systems
HEBRON, Ky.–(BUSINESS WIRE)–ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, today announced a strategic partnership with Medical Eyeglass Center (MEC), a nationally recognized, full-service o…
Lucidis® estabelece padrões elevados na cirurgia de catarata premium com desempenho visual completo
NEUCHÂTEL, Suíça–(BUSINESS WIRE)–A Swiss Advanced Vision anuncia novas evidências clínicas que confirmam o desempenho excepcional de sua lente intraocular (LIO) Lucidis®, fortalecendo sua posição como uma solução inovadora na cirurgia de catarata pre…
Samenvatting: Lucidis® stelt hoge normen voor hoogwaardige cataractchirurgie met volledig gezichtsvermogen
NEUCHÂTEL, Zwitserland–(BUSINESS WIRE)–Swiss Advanced Vision maakt nieuwe klinische resultaten bekend die de uitzonderlijke prestaties van zijn Lucidis® intraoculaire lens (IOL) bevestigen, waardoor zijn positie als baanbrekende oplossing in hoogwaar…
Lucidis®凭借全视程视觉表现，为高端白内障手术树立高标准
瑞士纳沙泰尔–(BUSINESS WIRE)–(美国商业资讯)– Swiss Advanced Vision公布最新临床证据，证实其Lucidis®人工晶体(IOL)表现卓越，进一步巩固其作为高端白内障手术颠覆性解决方案的地位。与传统的景深扩展型(EDOF)人工晶体不同，Lucidis®可提供媲美高端三焦点IOL的全视程视觉表现，同时保留对比敏感度、视觉质量，并将光晕和眩光等副作用降至最低，这也是其专利全折射式设计的标志性特征。 近期一项经同行评审的研究——由H. Naftali、W. Nas…
Riassunto: Lucidis® fissa standard elevati negli interventi di cataratta di alta qualità con prestazioni visive complete
NEUCHÂTEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision annuncia nuova evidenza clinica che conferma le eccezionali prestazioni della sua lente intraoculare (IOL) Lucidis®, rafforzando la sua posizione come soluzione innovativa nella chirurgia dell…
Lucidis® redefine los estándares de la cirugía de catarata prémium con una visión de rango completo
NEUCHÂTEL, Suiza–(BUSINESS WIRE)–Swiss Advanced Vision presentó nuevos datos clínicos que confirman el desempeño sobresaliente de su lente intraocular (LIO) Lucidis®, lo que consolida su lugar como una alternativa innovadora en la cirugía de catarata…
Lucidis® setzt mit seiner umfassenden Sehleistung neue Maßstäbe in der Premium-Kataraktchirurgie
NEUCHÂTEL, Schweiz–(BUSINESS WIRE)–Swiss Advanced Vision gibt neue klinische Erkenntnisse bekannt, die die außergewöhnliche Leistungsfähigkeit seiner Lucidis®-Intraokularlinse (IOL) bestätigen und seine Position als bahnbrechende Lösung in der Premiu…
Lucidis®憑藉全視程視覺表現，為頂級白內障手術樹立高標準
瑞士紐沙特–(BUSINESS WIRE)–(美國商業資訊)– Swiss Advanced Vision公布最新臨床證據，證實其Lucidis®人工水晶體(IOL)表現卓越，進一步鞏固其頂級白內障手術顛覆性解決方案的地位。與傳統的景深擴展型(EDOF)人工水晶體不同，Lucidis®可提供媲美頂級三焦點IOL的全視程視覺表現，同時保留對比敏感度、視覺品質，並將光暈和眩光等副作用降至最低，這也是其專利全折射式設計的代表性特徵。 近期一項經同儕審查的研究——由H. Naftali、W. Nass…
スイス・アドバンスト・ビジョン、Lucidis®でフルレンジの視力でプレミアム白内障手術の高い業界標準を確立
ヌーシャテル（スイス）–(BUSINESS WIRE)–（ビジネスワイヤ） — スイス・アドバンスト・ビジョン（SAV-IOL）は、Lucidis®眼内レンズ（IOL）の卓越した性能を裏付ける新たな臨床エビデンスを発表し、プレミアム白内障手術における革新的なソリューションプロバイダーとしての地位をさらに強化しました。従来の拡張焦点深度レンズとは異なり、Lucidis®は、プレミアム三焦点IOLに匹敵するフルレンジの視力性能を実現しつつ、コントラスト感度と視力の質を維持し、特許取得済みの完全屈折…
Hadley and UnitedHealthcare Vision Collaborate to Expand Emotional Support for Vision Loss
WINNETKA, Ill.–(BUSINESS WIRE)– #HadleyHelps–Hadley is working with UnitedHealthcare Vision to help ensure that more people experiencing vision loss have access to emotional support resources alongside their traditional eye care. As part of the coll…
EyeCare Partners 2025 Quality and Outcomes Report Demonstrates Visionary Care Provided Across U.S.
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners 2025 Quality & Outcomes Report offers a comprehensive look at clinical performance across a national, physician-led eye care network.
Sanaregen™ Vision Therapeutics Receives FDA Clearance for Clinical Trial to Treat Retinal Degeneration
NASHVILLE, Tenn.–(BUSINESS WIRE)– #ClinicalTrials–Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, today announced clearance by the U.S. Food and Drug Administration to conduct a Phase I/II clinical trial for SVT-001, i…
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance
NEUCHÂTEL, Switzerland–(BUSINESS WIRE)– #CataractSurgery–Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances.
Alcon Surpasses 175 Million IOLs Implanted Globally
GENEVA–(BUSINESS WIRE)–Alcon Surpasses 175 Million IOLs Implanted Globally
RevolutionEHR Launches RevPay, Redefining How Optometry Practices Manage Cash Flow
SAN DIEGO–(BUSINESS WIRE)– #DigitalPayments–RevolutionEHR, the market-leading optometry-first operating platform, today announced the launch of RevPay, its fully embedded payments solution designed to help practices get paid effortlessly while recov…
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent busine…
Warby Parker Announces Fourth Quarter and Full Year 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2025….
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Col…
Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
GENEVA–(BUSINESS WIRE)–Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales